End-to-End Cell Therapy Automation: An Immunotherapy Case Study
Consider automation early in the rollout of clinical translation and scale up of clinical-trial protocols.
As anticipation builds about accelerated clinical adoption of advanced cell therapies, more attention is turning to the underlying manufacturing strategies that will allow these therapies to benefit patients worldwide. While cell therapies hold great promise clinically, high manufacturing costs relative to reimbursement present a formidable roadblock to commercialization. Therefore, the need for cost effectiveness, process efficiency, and product consistency is driving efforts for automation in numerous cell therapy fields and particularly for T-cell immunotherapies.
Download the
BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook.
Article Details
BioPharm International
eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 10–18
Citation
When referring to this article, please cite it as J. Morrissey, N. Trainor, and Y. Shi, "End-to-End Cell Therapy Automation: An Immunotherapy Case Study," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
